GlassScriptPhysician profile
Jaclyn Ann Johnson
NPI 1700300373
$6,261.91
in general payments reported to CMS, 2019-2025
27 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $264 · 2021: $663 · 2022: $804 · 2023: $810 · 2024: $1,845 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,366.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,229.90 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $574.30 | 2024-2025 | Xdemvy |
| Allergan, INC. | $570.81 | 2019-2022 | |
| Glaukos Corporation | $551.16 | 2021-2025 | Idosetr |
| Alcon Vision LLC | $477.34 | 2021-2025 | Tryptyr, Rocklatan |
| Abbvie INC. | $438.78 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $394.56 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Apellis Pharmaceuticals, INC. | $255.40 | 2023-2025 | Syfovre |
| Amgen INC. | $224.16 | 2024-2025 | Tepezza |
| Dompe US, INC. | $219.26 | 2024-2025 | Oxervate |
| Sight Sciences, INC. | $190.17 | 2022-2023 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $169.32 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $160.00 | 2019-2023 | |
| Horizon Therapeutics Plc | $151.90 | 2022-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.74 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $109.31 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Harrow Eye, LLC | $87.89 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $61.88 | 2023-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Enterprises LLC | $39.29 | 2019 | |
| Lkc Technologies, INC. | $38.27 | 2025 | |
| Aerie Pharmaceuticals, INC. | $37.98 | 2021 | |
| Kala Pharmaceuticals, INC. | $36.88 | 2021 | |
| Akorn Operating Company LLC | $29.71 | 2021 | |
| Astellas Pharma US INC | $29.23 | 2024 | Izervay |
| Mallinckrodt Hospital Products INC. | $22.98 | 2025 | Acthar |
| Tearlab Corp | $18.63 | 2023 | Tearlab Osmolarity System |
| Thea Pharma INC. | $18.06 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.